Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com

Chemistry and Pharma Blogs:
Pharmalot
Org Prep Daily
On Pharma
One in Ten Thousand
Away From the Bench
QDIS Blog
Chemical Musings
In Vivo Blog
The Chemblog
Molecule of the Day
Kinase Pro
Drugs and Poisons
Jungfreudlich
Chembark
Social Detritus
Pharmagossip
Whistling in the Wind
Organometallic Current
Great Molecular Crapshoot
Post Doc Ergo Propter Doc
A Chemist's Lab Notebook
The Curious Wavefunction Totally Synthetic
Pharma's Cutting Edge
The F- Blog
Synthetic Environment
Atom Pusher
Chemistry World Blog
Carbon-Based Curiosities
Eye on FDA
Hdreioplus
Closeted Chemistry
Chemical Forums
Curly Arrow
Power of Goo
Carbon Tet
Totally Medicinal
Sceptical Chymist
Lamentations on Chemistry
PeterMR
Mining Drugs
Regulatory Affairs of the Heart
Making Graphite Work
Liquid Carbon
Half-Decent Pharma Blog


Science Blogs and News:
The Loom
Uncertain Principles
The Crimson Canary
Fierce Biotech
Blogs for Industry
The Futile Cycle
Omics! Omics!
Young Female Scientist
Notional Slurry
Life of a Lab Rat
TP With Page Numbers
Nobel Intent
SciTech Daily
Is This Thing On?
Science Blog
Eastern Blot
Oncology Updates
FuturePundit
Flags and Lollipops
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Daily Biomed
Voyage to Arcturus
Adventures in Ethics and Science
Terra Sigillata
Transterrestrial Musings
The Mass Spectrometry Blog
Nodal Point
Slashdot Science
A Scientist's Life
Living the Scientific Life
John Johnson
Humans in Science
Tobias Sing's Bioinformatics Blog
Speculist
Science, Shrimp and Grits
Biopeer
Cosmic Variance
The Capsule
Zeroth Order Approximation
Science Library Blog
Biology News Net


Medical Blogs
MedPundit
Med Tech Sentinel
DB's Medical Rants
Dr. Charles
RangelMD
GruntDoc
The Health Care Blog
Cut to Cure
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Asymmetrical Information
Belmont Club
Man Without Qualities
Belgravia Dispatch
Mickey Kaus
Colby Cosh
Progressive Reaction
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
Just Released the 2008 Tribalization of Business study - an in-depth look at how 140+ organizations are managing and measuring online communities

In the Pipeline

« Vial Thirty-Three: One Up, One Down | Main | Best When Used By. . . »

June 6, 2006

Vial Thirty-Three Rides Again

Email This Entry

Posted by Derek

Well, I got my repeat experiment set up before leaving work today. I could think of one variable I hadn't controlled for head-to-head yet, so I set up an extra couple of vials for that one. I'll try to get them analyzed tomorrow afternoon or Thursday morning, depending on how busy they are downstairs.

Getting this experiment going was a different feeling than when I ran it that Saturday. I was very eager and nervous that day, because I'd just had potentially great results and was ready to verify them as quickly as I could. (I had no way of knowing that the instrument needed for that was going to be out of service for two weeks, naturally). Today's repeat had some nervousness to it, but it was more along the lines of dread than the earlier anticipation.

I'm worried now that what I saw the first time is some kind of artifact, caused by something I haven't been able to anticipate. It looked very orderly, very clean, and quite believable, in its spectacular way. But yesterday's data had a more familiar look to it. It's really quite rare to get experimental results that are totally unequivocal - so many of them are a mixed, partly inexplicable bag. "Tell me - yes or no!" the experimentalist shouts, and the reply comes back "Dunno. . .sort of. . .I think. . .but maybe not, y'know?"

So by those standards, the first experiment, clean though it looked, is the suspicious anomaly. Here's hoping I'm wrong about being wrong.

Comments (4) + TrackBacks (0) | Category: Birth of an Idea


COMMENTS

1. Dave on June 6, 2006 10:42 PM writes...

All of us who have spent significant time at the bench can relate.

Fingers crossed that your earlier results are reproduced...

Permalink to Comment

2. Steven Jens on June 6, 2006 11:07 PM writes...

If the more recent results had been the first results you saw, would you have said, "well, that direction isn't any good -- let's try something else"? Or would you have tried again, anyway?

I'll be especially interested to know that if you turn out to win.

Permalink to Comment

3. Derek Lowe on June 7, 2006 6:23 AM writes...

Steven, I've thought about that question, too, and it gives me the shakes. It depends on just how scattery the data appeared to be. This second run isn't too good-looking, with (for example) two identical controls give quite different numbers.

If things had been all over the place, I might have suspected that something had been messed up. But if they had been only medium-ugly, I probably would have assumed that I was looking at a noisy version of nothing. Which is a pretty common result. . .

Permalink to Comment

4. highlyreactive on June 7, 2006 5:24 PM writes...

Derek, all of these birth of an idea posts are really fascinating but it makes me feel like chemistry is more alchemy or voodoo than reproducible science even though it isn't.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Pfizer's Prospects: Just Ducky
Happy Fourth of July
I Can Has Ugly Molecules?
More Pfizer Layoffs?
Leaving Comments: A Fix
The Gates Foundation: Dissatisfied With Results?
Another Alzheimer's Compound Goes Down
Unknown - But You Can Buy It